Target intelligence / Profile preview

Novel transcript, antisense to NCK2 (ENSG00000290119)

Target
ENSG00000290119
Molecular classification
Long non-coding RNA (lncRNA), Natural antisense transcript (NAT), Other (non-coding transcript)
01

Overview

The transcript referred to as "novel transcript, antisense to NCK2" (ENSG00000290119) is a natural antisense long non-coding RNA that overlaps the NCK2 gene in the human genome. NATs are a widespread class of regulatory RNA molecules that can interact with their 'sense' counterpart genes through several mechanisms, including transcriptional interference, RNA masking, and recruitment of epigenetic modifiers[1][2][3][4]. These processes can modulate gene expression, alternative splicing, mRNA stability, and chromatin state, impacting biological regulation. However, there is no published functional or disease association specific to ENSG00000290119, nor is it recognized as a druggable target or biomarker. NATs are an active area of research for understanding gene regulation, but many remain uncharacterized with respect to direct molecular or disease relevance.

Other names
ENSG00000290119antisense to NCK2NCK2-AS (by convention; not standardized)natural antisense transcript to NCK2
02

Mechanism of action

None known for drugs; hypothetical mechanisms could include RNA interference or antisense oligonucleotide-mediated degradation

03

Biological functions

Regulation of gene expressionTranscriptional interferenceRNA maskingEpigenetic modulationOther (gene silencing, if applicable; no direct evidence for ENSG00000290119)
04

Disease associations

Other (No direct association with disease for this transcript. In general, NATs can play roles in cancer and other diseases when their regulation affects disease-related genes)
05

Safety considerations

None known.
06

Interacting drugs

None known.
07

Biomarkers

None known.

Beyond the preview

Go deeper on Novel transcript, antisense to NCK2 (ENSG00000290119).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novel transcript, antisense to NCK2 (ENSG00000290119).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call